|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Cancer | |||||
| Thromboembolism | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Venous Thromboembolism | |||||
| 3 | More general conditions related to this trial | ||||
| Cardiovascular Diseases | |||||
| Embolism and Thrombosis | |||||
| Thrombosis | |||||
| Vascular Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| Arixtra | |||||
| Arixtra alone | |||||
| Arixtra + filter | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Fondaparinux | |||||
| Org 31540 | |||||
| 6 | More general drug interventions related to this trial | ||||
| Anticoagulants | |||||
| Cardiovascular Agents | |||||
| Fibrin Modulating Agents | |||||
| Fibrinolytic Agents | |||||
| Hematologic Agents | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| North Shore Long Island Jewish Health System | |||||
| GlaxoSmithKline | |||||